

Recent NSIP Intern Publications

1. **de Faria EB**, Barrow KR, **Ruehle BT**, Parker JT, Swartz E, Taylor-Howell C, Kieta KM, Lees CJ, Sleeper MM, Dobbin T, Baron AD, Mohindra P, **MacVittie TJ**. 2015 The Evolving Mcart Multimodal Imaging Core: Establishing a Protocol for Computed Tomography and Echocardiography in the Rhesus Macaque to Perform Longitudinal Analysis of Radiation-Induced Organ Injury. *Health Phys.* 109(5): 479-92.
2. Xie Y, Nakanishi T, Natarajan K, **Safren L**, Hamburger AW, Hussain A, **Ross DD**. 2015 Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells. *Biochim Biophys Acta* 1849(3): 317-27.
3. Muvarak N, **Kelley S**, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, **Scheibner K**, Rassool FV. 2015 c-Myc generates repair errors via increased transcription of alternative-NHEJ factors and PARP1 in tyrosine kinase-activated leukemias. *13*: 699-712.
4. Luncsford PJ, Manvilla BA, Patterson DN, Malik SS, Jin J, Hwang BJ, Gunther R, **Kalvakolanu S**, Lipinski LJ, Yuan W, Lu W, Drohat AC, Lu AL, **Toth EA**. 2013 Coordination of MYH DNA glycosylase and APE1 endonuclease activities via physical interactions. *DNA Repair (Amst)* 12(12): 1043-52.
5. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, **Phillips KK**, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, **Winkles JA**, Rosenblum MG. 2013 The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. *J Invest Dermatol.* 133(4): 1052-62.
6. Hu F, Gartenhaus RB, Zhao XF, Fang HB, **Minkove S**, **Poss DE**, **Rapoport AP**. 2013 c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas. *Leuk Res.* 37: 447-54.
7. Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, **McKenna C**, Bansal N, Ochoa A, **Davila E**. 2012 Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. *Cancer Res.* 72: 6209-16.
8. **Mahat DB**, Brennan-Laun SE, Fialcowitz-White EJ, Kishor A, Ross CR, Pozharskaya T, Rawn JD, Blackshear PJ, **Hassel BA**, **Wilson GM**. 2012 Coordinated expression of tristetraprolin post-transcriptionally attenuates mitogenic induction of the oncogenic Ser/Thr kinase Pim-1. *PLoS One.* 7:1371
9. Underwood KF, D'Souza DR, Mochin-Peters M, Pierce AD, Kommineni S, Choe M, **Bennett J**, Gnat A, Habtemariam B, MacKerell AD Jr, **Passaniti A**. 2012 Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity. *J Bone Miner Res.* 27: 913-25.
10. **Scheibner KA**, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, **Kelley SM**, Liu Z, Baer MR, Heimfeld S, Civin CI. 2012 MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3 θ . *PLOS One* 7: e50895.

11. **Hu F**, Gartenhaus RB, **Eichberg D**, Liu Z, Fang HB, **Rapoport AP**. 2010 PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. *Oncogene* 29: 5464-74.
12. Zhang Y, Ali TZ, Zhou H, D'Souza DR, Lu Y, **Jaffe J**, Liu Z, Passaniti A, **Hamburger AW**. 2010 ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. *Cancer Res.* 70: 240-8.
13. D'Souza DR, Salib MM, **Bennett J**, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, **Passaniti A**. 2009 Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. *J Biol Chem.* 284: 17947-55.